ImmunoGen's BB-10901 shows evidence of effectiveness against cancer in phase 1 trial

By Angela McDaniels

Seattle, Nov. 14 - ImmunoGen Inc. said its Tumor-Activated Prodrug technology program has yielded several clinical or preclinical findings pointing towards its value in fighting cancer.

Data to be presented on Wednesday at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia includes:

• The phase 1 trial of BB-10901 given intravenously to patients with small-cell lung cancer has shown evidence of clinical activity and includes a complete remission lasting at least 15 weeks in one patient;

• Preclinical studies have shown that the addition of ImmunoGen's huN901-DMI enhanced the anti-cancer activity of a number of chemotherapeutic agents in the treatment of small-cell lung cancer tumor models;

• Animal studies have shown the company's huC242-DM4 product candidate successfully accumulates in tumors.

ImmunoGen is based in Cambridge, Mass., and develops targeted anti-cancer biopharmaceuticals.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.